Sjögren’s lacrimal gland refers to the specific involvement of the tissues responsible for ocular lubrication within the context of a systemic disorder. In an optimal state of health, these structures secrete a constant volume of fluid that protects the cornea from external aggressions. However, this balance is broken when the organism activates a disproportionate autoimmune response against its own glandular cells. This pathology is characterized by the infiltration of lymphocytes into the exocrine glands, which interrupts the normal synthesis of fluids. Therefore, the lacrimal and salivary glands become direct targets of the immune system, causing structural damage that compromises their function. Consequently, the result is a state of chronic dryness that predominantly affects the female population.
Moreover, the reduction in the production of tears leaves the ocular surface exposed to constant friction from the eyelids. It is important to highlight that the lack of this protective film generates persistent irritation, manifesting as redness and burning. Nevertheless, the most common symptom described by patients is the annoying sensation of a foreign body or “grit” inside the eyes. As a result, Sjögren’s syndrome not only alters visual comfort but also endangers the integrity of long-term vision. The autoimmune disease acts silently but constantly, degrading the body’s ability to maintain the necessary moisture for the eyes to function correctly.
For this reason, the diagnosis of Sjögren’s lacrimal gland relies on clinical tests such as the Schirmer test, which measures the exact volume of secretion. In view of this, early identification is fundamental to avoid serious complications such as keratoconjunctivitis sicca or corneal scarring. Due to this condition, treatment must be constant and disciplined to supplement the organic deficiency of fluids. On the other hand, the frequent use of artificial tears and lubricating gels allows for restoring part of the lost protective function. Furthermore, modern approaches also include drugs to modulate the activity of the immune system and reduce glandular inflammation.
Finally, the comprehensive management of this condition seeks to improve ocular quality of life and prevent the functional deterioration of the face. Although damage to the gland can be irreversible, personal and medical care strategies manage to stabilize symptoms effectively. Accordingly, understanding how the defensive system attacks these tissues is key to the development of new biological therapies. In summary, the main goal is to normalize the environment of the ocular surface to minimize the impact of the autoimmune disorder. Ultimately, multidisciplinary follow-up ensures that both oral and ocular manifestations receive the necessary attention for general well-being.